1 Multidrug-resistant organism bloodstream infections in solid organ transplant recipients and

- 2 impact on mortality: a systematic review
- 3
- 4 Alice Liu¹, Adelaide Dennis¹, Zarin Fariha¹, Rekha Pai Mangalore¹, Nenad Macesic^{*1,2,3}
- 5

6 Affiliations

- ⁷ ¹ Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine,
- 8 Monash University, Melbourne, Australia
- 9 ² Centre to Impact AMR, Monash University, Clayton, Australia
- ³ Infection Prevention & Healthcare Epidemiology, Alfred Health, Melbourne, Australia.
- 11
- 12 * Corresponding Author
- 13 Dr. Nenad Macesic, Department of Infectious Diseases, The Alfred Hospital and School of
- 14 Translational Medicine, Monash University, Level 1 Alfred Lane House, Alfred Hospital, 55
- 15 Commercial Rd, Melbourne, VIC 3004, Australia. Email: <u>nenad.macesic1@monash.edu</u>
- 16
- 17 Word count (excluding abstract): 2465

18 Abstract (280 words)

- 19 Background: Bloodstream infections (BSI) cause significant morbidity and mortality in solid organ
- 20 transplant (SOT) recipients. There are few data regarding the contribution of multidrug-resistant
- 21 organisms (MDROs) to these infections.
- 22 Objectives: We evaluated the resistance-percentage of MDRO BSIs in SOT recipients and
- 23 assessed associated mortality.
- 24 Methods: A systematic review
- 25 Data sources: MEDLINE and Embase databases up to January 2024.
- 26 Study eligibility criteria: Studies of adult SOT recipients that quantify MDRO BSI resistance-
- 27 percentage and/or associated crude mortality. MDROs studied were carbapenem-resistant
- 28 Enterobacterales (CRE), Acinetobacter baumannii (CRAB) and Pseudomonas aeruginosa (CRPA),
- 29 third-generation-cephalosporin-resistant Enterobacterales (3GCR-E), methicillin-resistant
- 30 Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE).
- 31 *Participants:* Adult SOT recipients with a microbiologically confirmed BSI.
- 32 *Interventions:* Not applicable.
- 33 *Risk of bias assessment:* Newcastle Ottawa Scale.
- 34 *Methods of data synthesis:* MDRO BSI resistance-percentage and mortality outcomes were
- 35 reported as median (IQR) and crude mortality (%), respectively.
- 36 Results: Of 945 studies identified, 52 were included. Most were retrospective (41/52) and/or single
- 37 centre (37/52), and liver transplantation was the most studied SOT type (22/52). High resistance-
- percentages of BSIs were noted, ranging from 13.6% CRE for Enterobacterales to 59.2% CRAB for
- 39 *Acinetobacter baumannii*. Resistance-percentage trends decreased over time, but these changes
- 40 were not statistically significant. Asia had highest resistance-percentages for MRSA (86.2% [IQR
- 41 77.3-94.6%]), 3GCR-E (59.5% [IQR 40.5-66.7%]) and CRE (35.7% [IQR 8.3-63.1%]). North America
- 42 had highest VRE resistance-percentages (77.7% [IQR 54.6-94.7%]). Crude mortality was 15.4-
- 43 82.4% and was consistently higher than non-MDRO BSIs.
- 44 Conclusions: MDRO BSIs resistance-percentages were high for all pathogens studied (IQR 24.6-
- 45 69.4%) but there was geographical and temporal heterogeneity. MDRO BSIs were associated with

- 46 high mortality in SOT recipients. Microbiological and clinical data in this vulnerable population were
- 47 incomplete, highlighting the need for robust international multi-centre studies.

49 Introduction

50 Solid organ transplantation (SOT) provides a life-saving measure for patients with end-stage organ 51 failure. However, SOT recipients are at increased susceptibility to infection, which may result in 52 impaired graft function and adverse outcomes (1). Bloodstream infections (BSI) are a leading cause 53 of morbidity and mortality in this population (2-5), with mortality reaching 50% when associated with 54 septic shock (5, 6). Post-transplant BSIs result in prolonged hospital stays, need for re-admission 55 and substantial financial costs (4). Infections with multidrug-resistant organisms (MDROs) are 56 common among SOT recipients due to extended exposure to broad spectrum antimicrobials, 57 immunosuppressive medications, presence of chronic indwelling devices and frequent healthcare 58 exposure (7, 8). SOT itself has been described as an independent risk factor for certain MDRO 59 infections (8). MDRO infections are associated with greater mortality and increased risk of graft 60 failure than those caused by susceptible pathogens (7, 9, 10), posing a major challenge to individual 61 patient care. Furthermore, antimicrobial treatment options for these organisms are often limited and 62 may come with significant toxicities and cost. 63 64 While there are multiple reports of high resistance rates and poor outcomes of BSIs in SOT 65

66 temporal trends in these infections. In the absence of prior systematic review data, we provide a 67 comprehensive description of MDRO BSI resistance-percentages and associated mortality in SOT 68 recipients, focusing on clinically relevant pathogens that influence empirical and directed 69 antimicrobial decision making. The MDROs studied in this review represent a critical group of 70 pathogens that pose a significant global public health threat and are common causes of life-71 threatening hospital-acquired infection (14).

recipients (7, 11-13), there remains an urgent need to better understand the epidemiology and

72

73 Methods

74 Study selection

75 We performed a systematic review of all published literature describing resistance-percentage 76 and/or mortality of BSIs due to MDROs among adult SOT recipients. Six MDROs were selected

77 from the WHO Bacterial Priority Pathogens (2024 update) due to their relevance for SOT recipients 78 (15): carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter 79 baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), third generation 80 cephalosporin-resistant Enterobacterales (3GCR-E), vancomycin-resistant Enterococcus faecium 81 (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). 82 83 We included all published studies (retrospective and prospective) of adult (≥18 years) SOT 84 recipients (heart, lung, liver, kidney, pancreas, intestinal and multivisceral) that quantified BSIs due 85 to MDROs and/or associated crude mortality rates. Additional studies were identified from review of 86 reference lists. Only full text studies were included in the analysis. Case reports, expert opinion 87 pieces, narrative reviews, pharmacokinetic/pharmacodynamic studies, and studies of colonisation or 88 surveillance blood cultures were excluded. Studies that lacked quantitative data of the proportion of 89 BSIs due to MDROs were also omitted. 90 91 The primary outcome was proportion of BSIs due to MDROs, expressed as median [IQR]. The 92 secondary outcome was crude mortality due to MDRO BSI, expressed as a proportion (%). 93 94 Search strategy 95 A literature search was conducted in the Embase and MEDLINE databases in accordance with 96 guidelines from the Preferred Reporting Items for Systematic Reviews and Meta 97 Analyses (PRISMA) statement (16). No time or language restriction was applied. The following key 98 words and their related MeSH and Emtree search terms were used in various combinations: 99 bloodstream infection, bacteraemia, sepsis, solid organ transplantation, organ graft, multidrug-100 resistant organism, antimicrobial resistance, carbapenem resistance, extended-spectrum beta-101 lactamase, vancomycin resistance, methicillin resistance, Enterobacterales, Acinetobacter, 102 Pseudomonas, Staphylococcus and Enterococcus. Full search strategy results are provided in 103 Supp. Tables 1 and 2. The study was registered with PROSPERO (CRD42023466931). 104

105 Data extraction and analysis

106 Title and abstract screening were performed by AL. Full text screening was performed by three 107 reviewers (AL, AD, ZF), who also extracted data independently. Conflicts between reviewers on 108 eligibility assessments and data extraction results were resolved through discussion and consensus 109 among all authors. Duplicate studies were removed via Covidence systematic review software 110 (Veritas Health Innovation, Melbourne, Australia) and manual checking. Data were extracted using a 111 custom extraction template covering the following variables: study design, year and location, study 112 population size, type/s of transplant, MDRO species and their frequency, associated crude mortality 113 (where available) and antimicrobial susceptibility testing methods. Statistical analyses and 114 visualisations were performed with R v4.3.0 (2023). Specifically, we applied a linear regression 115 analysis using the 'Im' function to assess the presence of a trend in MDRO resistance-percentages 116 over time. 117 118 Risk of bias assessment 119 Quality assessment was conducted using the Newcastle Ottawa Scale (NOS) (17). For the NOS

assessment, exposure was defined as BSI due to MDRO. Comparability of cohorts was based on controlling for baseline patient demographics and immunosuppression regimen. Assessment of MDRO proportions was through microbiological confirmation with a description of the antimicrobial susceptibility methods included. Assessment of mortality outcomes was through an independent assessment or record linkage. There was no minimum follow-up period, and the shortest study period was 12 months (18). Studies with a NOS score of 7 or greater were included in the final analysis.

128 Results

129 Study characteristics

130 A total of 1137 studies were identified. After removal of duplicates, 945 were screened, of which 114 131 studies were retrieved and 52 included in the final analysis (Fig. 1). Reasons for exclusion (62 132 studies) were incorrect study design, outcomes not specific to BSIs or insufficient data on 133 antimicrobial susceptibility. Most studies were retrospective (41/52, 78.8%) and single-centre (37/52, 134 71.2%). Of the studies focused on a single transplant type, liver transplant was the most studied 135 (22/52, 42.3%), followed by kidney transplant (5/52, 9.6%). Eighteen (34.6%) studies included 136 pooled multiple transplant types in their analysis. Study population size was variable, ranging from 137 14 BSI episodes over a 3-year period (19) to 988 episodes over 10 years (8). Full details on the 138 characteristics of the included studies are provided in Supp. Table 3. Quality assessment using the

139 NOS is described in Supp. Tables 4 and 5.

140

141 Pooled estimates of MDRO BSIs in SOT recipients

142 Proportion of BSIs due to MDROs was reported in 49/52 studies with only crude mortality reported

in the remaining three studies. MDRO BSI resistance-percentages are shown in Table 1 and Fig. 2A

and ranged from 13.6% (IQR 8.7-37.0%) carbapenem resistance in Enterobacterales to 59.2% (IQR

145 50.0-77.4%) carbapenem resistance in *Acinetobacter baumannii*. We analysed MDRO resistance-

146 percentages over time and noted reducing trends for all MDROs except CRAB, but these changes

147 were not statistically significant (Table 1, Fig. 2B and Supp. Table 6).

148

149 MDRO BSI resistance-percentage varied by region (Table 1), with Asia having highest median

150 resistance-percentages of MRSA (86% [IQR 77-95%]), 3GCR-E (60% [IQR 40-67%]), CRE (36%

151 [IQR 8-63%]) and CRAB (60% [IQR 54-89%]). North America had highest VRE resistance-

152 percentages (median 78% [IQR 55-95%]). South America had highest CRPA resistance-percentage

153 (88%), but this was based on results of a single study.

155	Liver transplantation was the most studied transplant type with the following median MDRO
156	resistance-percentages: CRE 9.5% (IQR 4.7-14.3%), 3GCR-E 40.4% (IQR 26.7-59.5%), CRAB
157	72.3% (IQR 48.2-93.3%), CRPA 33.3% (IQR 9.1-5.7%), VRE 34.0% (IQR 24.3-69.8%) and MRSA
158	80.0% (IQR 48.7-96.4%). Kidney transplantation had sufficient data for analysis of 3GCR-E
159	resistance-percentage (median 32.4% [IQR 21.1-65.3%]), but there were too few studies to
160	determine these for other transplant type/MDRO combinations.
161	
162	Pooled estimates of mortality due to MDRO BSI in SOT recipients
163	Mortality associated with MDRO BSI was reported in 17/52 (32.7%) studies (Table 2). The method
164	of reporting varied between studies, including different time intervals. In most studies (13/17, 76.5%)
165	mortality was recorded by attributable organism, however 3 studies pooled multiple MDRO
166	pathogens for mortality outcomes. Within these limits, crude mortality due to MDRO BSI ranged
167	from 15.4% (VRE 30-day mortality in liver transplant recipients) (20) to 82.4% (CRE mortality in liver
168	transplant recipients admitted to intensive care) (21). Excluding patients in the intensive care
169	setting, crude mortality remained as high as 65.5% (CRAB 10- and 30-day mortality in liver
170	transplant recipients) (22). Where mortality due to MDRO BSI was assessed alongside drug-
171	susceptible BSI, MDRO BSIs were consistently associated with a higher mortality rate irrespective
172	of MDRO or transplant type (Table 2). For individual MDROs, MRSA and VRE-associated mortality
173	were most frequently reported, with a median crude mortality of 36.1% (IQR 19.3–56.3%) and
174	37.2% (IQR 30.9-42.5%), respectively. There was insufficient data for pooled analysis for all other
175	MDROs studied.
176	

177 Discussion

Our systematic review aimed to quantify the burden of MDRO BSIs in SOT recipients and
successfully consolidated global antimicrobial resistance (AMR) data for multiple clinically relevant
pathogens that cause BSIs in SOT recipients. We observed high resistance-percentages for BSIs in
SOT recipients, ranging from median 13.6% for CRE BSIs to median 56.2% for CRAB BSIs.

However, there was considerable heterogeneity in resistance-percentages across different regions and time periods. While there were decreasing trends in MDRO BSIs over time, CRAB remained an exception. MDRO BSIs were associated with high crude mortality in SOT recipients, ranging from 15% up to 82.4% in one study in an intensive care setting (21).

186

187 We noted prominent differences in MDRO BSI burden across regions. A key question arises 188 regarding comparison with AMR burden in the general population. Asia had highest resistance-189 percentages for multiple pathogens (MRSA, 3GCR-E, CRE and CRAB). These were higher than in 190 the general hospitalised population in Asia (30.5-49.0% for MRSA BSIs, 36.0-57.2% for 3GCR-E 191 BSIs and 23.1-26.1% for CRE BSIs) (23, 24) but lower for CRAB BSIs (median 60% in SOT 192 recipients vs. 71.5-90.5%) (23, 24). Most Asian studies were confined to liver transplant, which is 193 more commonly associated with post-operative bacterial infections (25-27). This, combined with 194 high overall rates of AMR in many Asian countries may explain the high resistance-percentages for 195 BSIs in SOT recipients we observed in this region (23, 28, 29). North America exhibited the highest resistance percentage of VRE (median 76.6%), aligning with surveillance data demonstrating >70% 196 197 of US hospital Enterococcus faecium isolates are VRE (30). Conversely, Europe had the lowest 198 VRE resistance-percentages (median 3.0%). European general VRE surveillance data range widely 199 from <1% in Holland to 45% in Greece (31). In our review, Spanish (4/16, 25%) and Italian studies 200 (4/16, 25%) were most frequently represented, and our VRE findings reflected surveillance data 201 rates from both countries (3% and 11%, respectively) (31).

202

Resistance-percentages decreased over time for several of the pathogens studied (MRSA, VRE,
3GCR-E, CRE and CRPA). While these trends did not reach statistical significance, this finding
contrasts to global observations of increasing MDRO prevalence over time (32-35). MRSA is unique
in demonstrating an early rise and subsequent fall in its prevalence across multiple geographic
regions over the last two decades (36), potentially explaining our findings of reducing MRSA trends.
The decreasing prevalence of other MDROs over time may potentially be attributed to
improvements in infection control measures, better detection of donor-derived infections and

210 changes in antibiotic prophylaxis prescribing practices over time (37, 38). Furthermore, global AMR 211 surveillance methods are not standardised nor is coverage universal (39), and the resistance-212 percentage rates noted in this study represent specialised transplant centres rather than all 213 healthcare facilities. In contrast, we noted increasing CRAB resistance-percentages in our study, 214 which may reflect the contribution of frequent intensive care unit admission following SOT, with 215 healthcare-associated horizontal transmission of CRAB well described in this setting (40, 41). 216 217 We found high crude mortality rates among patients with MDRO BSIs ranging from 15.4 to 82.4%. 218 However, this was based on limited data (17 studies), with almost all studies reporting on <100 SOT 219 recipients with MDRO BSI. These findings contrast with prior reports that noted lower mortality in 220 SOT recipients with sepsis in the early post-transplant period than in non-SOT patients (42, 43). 221 However, these studies did not distinguish between BSI with susceptible and drug-resistant 222 pathogens. Even fewer studies (n=4) compared mortality between MDRO and non-MDRO BSIs in 223 SOT recipients, but in these studies MDRO BSIs were consistently associated with a higher crude 224 mortality rate (10, 20, 44, 45). This may reflect use of empiric antibiotics with inadequate spectra of 225 activity. Alterations in the pathophysiology of different SOT recipients may also account for the high 226 overall mortality rate in this population. For example, heart transplant recipients have higher risk of 227 cardiogenic shock complicating septic shock, while lung transplant recipients are at greater risk of 228 respiratory failure requiring intubation and intensive care support (46).

229

230 Our study has several limitations. Firstly, the included studies were heterogeneous in their 231 population size and follow-up period. It was therefore not feasible to conduct a meta-analysis of the 232 study outcomes. The transplant type strongly influences the primary site of infection and associated 233 sepsis (47). We were unable to stratify MDRO frequency-percentages by transplant type because 234 many studies pooled multiple transplant types in their analyses. Additionally, data on prescribing 235 practices were inconsistently recorded across studies and there is a high likelihood that there were 236 geographical and temporal differences in therapeutic and prophylactic antimicrobial prescribing and 237 immunosuppression regimens. These differences would influence MDRO BSI frequency-

percentages observed. Finally, mortality data were not reported in a standardised manner, varying
 from 5-day to 1-year mortality figures, limiting pooled analysis and comparison between studies.

241 Our review underscores several priorities in the care of SOT recipients. Our findings of high 242 resistance-percentages for BSIs and significant associated mortality highlight that prevention of 243 MDRO acquisition remains paramount. This includes but is not limited to proactive antimicrobial 244 stewardship pre- and post-transplantation to reduce selection pressure, infection control measures 245 to limit cross-transmission in hospital settings, and regular review of immunosuppressant 246 medications and indwelling devices to reduce the risk of colonisation. Strategies for early 247 identification of BSIs caused by MDROs may also help in timely antibiotic rationalisation and limiting 248 the emergence of MDROs in the transplant population, such as continued development of rapid 249 laboratory diagnostics and antimicrobial susceptibility testing methods, and implementation of 250 protocolised surveillance testing programs for donors and recipients.

251

252 We also identified future research priorities. Our review found a paucity of transplant type-specific 253 microbiological data, non-standardised mortality reporting methods and a reliance on retrospective 254 and/or single centre data resulting in wide variation in study size. It has been noted that frequency 255 measures such as resistance-percentages are of limited use without accompanying population 256 resistance-percentage estimates or incidence-density data (48), which was also evident in our 257 review. Future work should focus on longitudinal prospective data collection using consistent 258 metrics, capturing both clinical and microbiological outcomes and representing SOT types 259 proportionately. This presents an opportunity to further develop and implement larger scale 260 transplant registries such as the Swiss Transplant Cohort study (11, 13) which capture infectious 261 complications and corresponding microbiological data.

262

263 Conclusion

264 Our findings reinforce that SOT recipients are highly vulnerable to MDRO BSIs and experience 265 substantial associated mortality. We identified marked geographical variation in the proportion of

266	MDRO BSIs, which warrants ongoing characterisation in future studies. While there was a trend
267	towards reducing resistance-percentages of several MDROs, this was not statistically significant
268	and certain pathogens were under-represented. We noted gaps in the reporting of transplant type-
269	specific data and a paucity of standardised mortality outcomes. Our study highlights the urgent need
270	for robust international multi-centre cohort studies that adequately capture microbiological data and
271	BSI clinical outcomes to guide prevention and empirical treatment strategies in this highly
272	vulnerable patient group.
273	
274	Transparency declarations
275	None to declare
276	
277	Funding
278	This work was supported by the National Health and Medical Research Council of Australia
279	(Emerging Leader 1 Fellowship APP1176324 to N.M.).
280	The funders had no role in study design, data collection and interpretation, or the decision to submit
281	the work for publication.

283 References

Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601 14.

Adelman MW, Connor AA, Hsu E, Saharia A, Mobley CM, Victor DW, 3rd, et al. Bloodstream
 infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance (2016 JAC Antimicrob Resist. 2024;6(1):dlad158.

3. Gavalda J, Aguado JM, Manuel O, Grossi P, Hirsch HH, Hosts ESGoliC. A special issue on
 infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:1-3.

- Kritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. Virulence.
 2016;7(3):329-40.
- 5. Candel FJ, Grima E, Matesanz M, Cervera C, Soto G, Almela M, et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc. 2005;37(9):4097-9.
- Moreno A, Cervera C, Gavalda J, Rovira M, de la Camara R, Jarque I, et al. Bloodstream
 infections among transplant recipients: results of a nationwide surveillance in Spain. Am J
 Transplant. 2007;7(11):2579-86.
- Adelman MW, Connor AA, Hsu E, Saharia A, Mobley CM, Victor DW, III, et al. Bloodstream
 infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance
 (2016–21). JAC-Antimicrobial Resistance. 2024;6(1).
- Anesi JA, Lautenbach E, Tamma PD, Thom KA, Blumberg EA, Alby K, et al. Risk Factors for
 Extended-Spectrum beta-lactamase-Producing Enterobacterales Bloodstream Infection Among
 Solid-Organ Transplant Recipients. Clin Infect Dis. 2021;72(6):953-60.
- Kadri SS, Lai YLE, Ricotta EE, Strich JR, Babiker A, Rhee C, et al. External Validation of
 Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection
 Using Electronic Health Record Data From 140 US Hospitals. Open Forum Infect Dis.
 2019;6(4):ofz110.
- Anesi JA, Lautenbach E, Thom KA, Tamma PD, Blumberg EA, Alby K, et al. Clinical
 Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in
 Solid Organ Transplant Recipients. Transplantation. 2023;107(1):254-63.
- 11. van Delden C, Stampf S, Hirsch HH, Manuel O, Meylan P, Cusini A, et al. Burden and
 Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss
 Transplant Cohort Study. Clin Infect Dis. 2020;71(7):e159-e69.
- Ye QF, Zhao J, Wan QQ, Qiao BB, Zhou JD. Frequency and clinical outcomes of ESKAPE
 bacteremia in solid organ transplantation and the risk factors for mortality. Transpl Infect Dis.
 2014;16(5):767-74.
- Neofytos D, Stampf S, Hoessly LD, D'Asaro M, Tang GN, Boggian K, et al. Bacteremia
 During the First Year After Solid Organ Transplantation: An Epidemiological Update. Open Forum
 Infect Dis. 2023;10(6):ofad247.
- Parker MT, Organization WH. Hospital-acquired infections: guidelines to laboratory methods:
 World Health Organization. Regional Office for Europe; 1978.
- WHO. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health
 importance to guide research, development and strategies to prevent and control antimicrobial
 resistance. Geneva; 2024.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj.
- 327 2021;372:n71.
- Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa
 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from:
 http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
- 18. Gagliotti C, Morsillo F, Moro ML, Masiero L, Procaccio F, Vespasiano F, et al. Infections in
- liver and lung transplant recipients: a national prospective cohort. Eur J Clin Microbiol Infect Dis.
 2018;37(3):399-407.
- 19. Karruli A, de Cristofaro J, Andini R, Iossa D, Bernardo M, Amarelli C, et al. Risk Factors and
- Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center
 Experience. Microorganisms. 2021;9(6).

337 20. Dubler S, Lenz M, Zimmermann S, Richter DC, Weiss KH, Mehrabi A, et al. Does 338 vancomycin resistance increase mortality in Enterococcus faecium bacteraemia after orthotopic liver transplantation? A retrospective study. Antimicrob Resist Infect Control. 2020;9(1):22. 339 340 Mouloudi E, Massa E, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T, et al. 21. 341 Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among 342 intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact 343 of resistance on outcomes. Transplant Proc. 2014;46(9):3216-8. 344 Min EK, Yim SH, Choi MC, Lee JG, Joo DJ, Kim MS, et al. Incidence, mortality, and risk 22. factors associated with carbapenem-resistant Acinetobacter baumannii bacteremia within 30 days 345 346 after liver transplantation. Clin Transplant. 2023;37(5):e14956. 347 Yang W, Ding L, Han R, Yin D, Wu S, Yang Y, et al. Current status and trends of 23. 348 antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from 349 2018 to 2022. One Health Advances. 2023;1(1):8. 350 24. Kim D, Yoon EJ, Hong JS, Choi MH, Kim HS, Kim YR, et al. Major Bloodstream Infection-351 Causing Bacterial Pathogens and Their Antimicrobial Resistance in South Korea, 2017-2019: Phase 352 I Report From Kor-GLASS. Front Microbiol. 2021;12:799084. 353 Kim SI. Bacterial infection after liver transplantation. World J Gastroenterol. 25. 354 2014;20(20):6211-20. 355 26. Kim SH, Mun SJ, Ko JH, Huh K, Cho SY, Kang CI, et al. Poor outcomes of early recurrent 356 post-transplant bloodstream infection in living-donor liver transplant recipients. Eur J Clin Microbiol 357 Infect Dis. 2021;40(4):771-8. 358 Kim YJ, Kim SI, Wie SH, Kim YR, Hur JA, Choi JY, et al. Infectious complications in living-27. 359 donor liver transplant recipients: a 9-year single-center experience. Transpl Infect Dis. 360 2008;10(5):316-24. 361 28. Qiao M, Ying GG, Singer AC, Zhu YG. Review of antibiotic resistance in China and its 362 environment. Environ Int. 2018;110:160-72. 363 29. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 364 2011;37(4):291-5. 365 30. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department 366 of Health and Human Services, CDC; 2019. 367 31. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence 368 and spread of vancomycin resistance among enterococci in Europe. Eurosurveillance. 369 2008;13(47):19046. 370 Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, et al. Global spread of carbapenem-resistant 32. 371 Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. 372 Microbiol Res. 2023;266:127249. 373 33. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing 374 Enterobacteriaceae in Europe. Euro Surveill. 2008;13(47):19044. 375 34. Proportion of bloodstream infection due to methicillin-resistant Staphylococcus aureus 376 (MRSA) (%) [Internet]. WHO. 2024. Available from: https://data.who.int/indicators/i/5dd9606. 377 Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, et al. Comparison of the global 35. 378 prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between 379 healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob Resist. 380 2022;4(3):dlac048. 381 36. Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-Year Trends in 382 Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial 383 Surveillance Program. Open Forum Infect Dis. 2019;6(Suppl 1):S47-s53. 384 37. Smibert O, Satlin MJ, Nellore A, Peleg AY. Carbapenem-Resistant Enterobacteriaceae in 385 Solid Organ Transplantation: Management Principles. Curr Infect Dis Rep. 2019;21(7):26. 386 38. Nellore A, Huprikar S, Practice AICo. Vancomycin-resistant Enterococcus in solid organ 387 transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases 388 Community of Practice. Clin Transplant. 2019;33(9):e13549. 389 39. WHO. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014. 390 40. Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant Acinetobacter 391 baumannii: A challenge in the intensive care unit. Front Microbiol. 2022;13:1045206.

41. Doughty EL, Liu H, Moran RA, Hua X, Ba X, Guo F, et al. Endemicity and diversification of
 carbapenem-resistant Acinetobacter baumannii in an intensive care unit. Lancet Reg Health West
 Pac. 2023;37:100780.

42. Donnelly JP, Locke JE, MacLennan PA, McGwin G, Jr., Mannon RB, Safford MM, et al.
Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe
Sepsis. Clin Infect Dis. 2016;63(2):186-94.

Kalil AC, Syed A, Rupp ME, Chambers H, Vargas L, Maskin A, et al. Is bacteremic sepsis
associated with higher mortality in transplant recipients than in nontransplant patients? A matched
case-control propensity-adjusted study. Clin Infect Dis. 2015;60(2):216-22.

401 44. Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Roca J, et al. Risk factors and outcomes of
402 bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients.
403 Transplantation. 2013;96(9):843-9.

404 45. Ye QF, Zhou W, Wan QQ. Donor-derived infections among Chinese donation after cardiac 405 death liver recipients. World J Gastroenterol. 2017;23(31):5809-16.

406 46. Eichenberger EM, Ruffin F, Sharma-Kuinkel B, Dagher M, Park L, Kohler C, et al. Bacterial
407 genotype and clinical outcomes in solid organ transplant recipients with Staphylococcus aureus
408 bacteremia. Transpl Infect Dis. 2021;23(6):e13730.

409 47. Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et al. Early 410 bacteremia after solid organ transplantation. Transplant Proc. 2009;41(6):2262-4.

411 48. Pezzani MD, Arieti F, Rajendran NB, Barana B, Cappelli E, De Rui ME, et al. Frequency of

- 412 bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research
- and discovery of new therapies in Europe: a systematic review. Clin Microbiol Infect. 2024;30 Suppl
- 414 1:S4-S13.

416 Fig. 1: PRISMA flow diagram







Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales; CRAB – carbapenem-resistant *Acinetobacter baumannii*; CRE – carbapenem-resistant Enterobacterales; CRP – carbapenem-resistant *Pseudomonas aeruginosa;* MRSA –methicillin-resistant *Staphylococcus aureus*; VRE – vancomycin-resistant *Enterococcus*.

	Pooled (n = 49)	2002 – 2010 (n = 10)	2011 – 2015 (n = 15)	2016 – 2020 (n = 12)	2021 – 2024 (n = 12)	Europe (n = 16)	North America (n = 12)	South America (n = 4)	Asia (n = 17)
3GCR-E, median (IQR)	38.2%	42.3%	30.0%	33.8%	40.0%	29.3%	33.5%	43.4%	63.1%
(% of Enterobacterales)	(27–49%)	(33.6–50.9%)	(27.6–56.5%)	(20.8–40.8%)	(35.0–47.5%)	(21.2–40.5%)	(30.4–36.2%)	(41.9–44.9%)	(45.2–72.9%)
CRE, median (IQR)	13.6%	0.5%		28.6%	6.3%	44.00/*	12.9%		35.7%
(% of Enterobacterales)	(8.7–37.0%)	9.5%*	45.5%"	(14.3–61.9%) (3.6–9.1%)	14.3%"	(7.8–13.6%)	NK	(8.3–63.1%)	
CRAB, median (IQR)	59.2%	60.0%/*	54.2%	72.4%	94 69/ *	50.0%	ND	53.6%	60.0%
(% of A. baumannii)	(50.0–77.4%)	60.0%^	(48.2–73.3%)	(6.2–83.6%)	04.0%	(50.0–61.4%)	INIT	(42.9–64.3%)	(54.2–88.7%)
CRPA, median (IQR)	33.3%	ND	33.3%	32.4%	17.0%	45.2%	38.9%	97.5*	27.5%
(% of <i>P. aeruginosa</i>)	(24.3–43.8%)	INIT	(33.3–74.3%)	(27.9–36.8%)	(6.8–29.9%)	(25.0–61.4%)	(36.1–41.7%)	07.5	(21.0–32.8%)
MRSA, median (IQR)	50.4%	77.8%	56.0%	77.9%	31.5%	31.7%	50.5%	64.3%	86.2%
(% of S. aureus)	(36.4–86.7%)	(47.40–100%)	(35.5–84.3%)	(73.9–81.8%)	(15.6–47.4%)	(22.0–46.6%)	(38.1–77.8%)	(53.6–75.0%)	(77.3–94.6%)
VRE, median (IQR)	38.1%	55.6%	15.0%	53.0%	36.9%	3.0%	76.6%	38 60/.*	32.3%
(% of <i>E. faecium</i>)	(3.0–67.6%)	(27.88–77.8%)	(0.0–36.1%)	(28.4–76.0%)	(8.9–62.2%)	(0.0–23.5%)	(57.2–89.4%)	30.0%	(6.6–51.2%)

Table 1: Proportions of bloodstream infections caused by resistant organisms in solid-organ transplant recipients by time period and region

*only single studies available, unable to calculate IQR. NR = not reported.

Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales; CRAB – carbapenem-resistant *Acinetobacter baumannii*; CRE – carbapenem-resistant Enterobacterales; CRP – carbapenem-resistant *Pseudomonas aeruginosa;* MRSA – methicillin-resistant *Staphylococcus aureus*; VRE –

vancomycin-resistant Enterococcus.

Author	Year	Location	Study characteristics	Study population characteristics including SOT type	Organism/s studied	Mortality	
Circela et el	0004	Linite d Otataa	Retrospective, single	233 liver transplant recipients	MRSA	MRSA mortality 9/33 (27.3%)	
Singh et al.	2004	United States	centre, observational study	between 1989 – 2003	VRE	VRE mortality 4/8 (50.0%)	
			Prospective, multicentre,	56 lung transplant recipients with			
Husain et al.	2006	United States	observational study (4	bacteraemia between July 2000 –	MRSA	MRSA mortality 1/6 (16.7%)	
				sites)	February 2004		
			Potrospoctivo, singlo	205 liver transplant recipients			
Bedini et al.	2007	Italy	centre observational study	between October 2000 - September	MRSA	MRSA 30-day mortality 3/5 (60.0%)	
				2005			
					MRSA		
	2009	09 Korea	Retrospective, single Korea centre, observational study	144 liver transplant recipients between January 2005 – September 2007	VRE	VRE mortality 2/5 (40.0%)	
Kim et al.					ESBL		
					CRAB		
							CRPA
					MRSA	Dealed MDRO martality 10/54	
	2013	013 Spain	Prospective single	Prospective, single contro	190 SOT recipients (liver, kidney and	VRE	(35.2%)
Bodro et al.			observational study	heart) between January 2007 – December 2012	3GCR-E	(33.2%) Pooled non-MDRO mortality 32/185	
					CRAB	(14.4%)	
					CRPA	(14.470)	
Aguiar et al.	2014			Retrospective, single	759 kidney and 258 liver transplant		
		.014 Brazil	centre, observational study	recipients between January 2000 –	3GCR-E	ESBL 30-day mortality 10/39 (25.6%)	
			······································	September 2008			

Table 2: Mortality due to bloodstream infection from multidrug resistant organism/s in solid organ transplant recipients:

Mouloudi et al.	2014	Greece	Prospective, single centre, observational study	17 Liver transplant recipients admitted to the intensive care unit between January 2008 – December 2011	CRE (CRKP only)	CRKP mortality 14/17 (82.4%)
Ye et al.	2014	China	Retrospective, multicentre, observational study (2 sites)	71 SOT recipients between January 2002 – August 2013	MRSA VRE 3GCR-E CRE CRAB	Pooled MDRO 30-day mortality 22/39 (56.4%) Pooled non-MDRO 30-day mortality 12/32 (37.5%)
Zhou et al.	2015	China	Retrospective, multicentre, observational study (2 sites)	275 liver transplant recipients with <i>S.</i> <i>aureus</i> BSI between January 2001 – December 2014	MRSA	MRSA mortality 9/20 (45.0%)
Kim et al.	2018	Korea	Retrospective, single centre, observational study	393 liver transplant recipients from January 2008 – April 2015	CRAB	CRAB 1-year mortality 5/14 (35.7%)
Kim et al.	2019	Korea	Retrospective, single centre, observational study	536 liver transplant recipients between January 2008 – December 2017	VRE	VRE 1-year mortality 9/25 (36.0%)
Dubler et al.	2020	Germany	Retrospective, single centre, observational study	177 liver transplant recipients between January 2006 – December 2016 who had an E. faecium bacteraemia	VRE	VRE 30-day mortality 6/39 (15.4%) VRE 90-day mortality 15/39 (38.5%) Non-VRE 30-day mortality 15/138 (10.9%) Non-VRE 90-day mortality 43/138 (31.2%)

Mercuro et al.	2020	United States	Retrospective, single centre, cohort study	58 hospitalised SOT recipients (3 heart, 3 lung, 33 liver, 6 kidney, 10 intestinal, 3 multivisceral) with E	VRE	VRE mortality - 13/41 (31.7%)	
				faecium BSI between January 2013 –			
				February 2019			
					MRSA		
	2021	Korea	Retrospective, single centre, observational study	727 liver transplant recipients between January 2008 – December 2016	VRE		
Kim et al					3GCR-E	Pooled MDRO 90-day mortality 15/39	
Riff et al.					CRE	(38.5%)	
					CRAB		
					CRPA		
	2022	US	Potrospostivo multicontro	117 liver transplant recipients			
Lee et al.			cohort study	(including 22 multivisceral) between	VRE	VRE 1-year mortality 29/108 (26.9%)	
				January 2006 – December 2016			
				897 SOT recipients (69 episodes of			
	2023	3 United States	Patrospostivo	Retrospective multicentre	heart transplant, 58 lung, 278 liver,		CRE 60-day mortality 33/70 (47.1%)
Anesi et al.			cohort study	514 kidney, 27 pancreas) with an	CRE	Non-CRE 60-day mortality 102/827	
				Enterobacterales BSI between 2005		(12.3%)	
				- 2018			
			Retrospective, single	1051 liver transplant recipients		CRAB 5-day mortality 17/29 (58.6%)	
Min et al.	2023	Korea	centre, nested case control	between September 2005 –	CRAB	CRAB 10-day mortality 19/29 (65.5%)	
			study	December 2021		CRAB 30-day mortality 19/29 (65.5%)	
1							

Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales, BSI – bloodstream infection, CRAB – carbapenem-resistant *Acinetobacter baumannii*, CRE – carbapenem-resistant Enterobacterales, CRKP – carbapenem-resistant *Klebsiella pneumoniae*, CRPA – carbapenemresistant *Pseudomonas aeruginosa*, MDRO – multi-drug resistant organism/s, MRSA – methicillin-resistant *Staphylococcus aureus*, SOT – solid organ transplant, VRE – vancomycin-resistant *Enterococcus faecium*.